You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of a Wearable Fluorescence Imaging Device for IntraoperativeIdentification of Brain Tumors
SBC: BIOPTICS TECHNOLOGY LLC Topic: 102ABSTRACT Approximately 700,000 people in the United States are diagnosed with a primary brain tumor. Of these, malignant gliomas (MGs) account for approximately 40% of all intracranial tumors, with an overall survival rate of only ~34%. Surgical resection remains the cornerstone of therapy and the extent of resection correlates with survival. Fluorescence imaging has emerged as an adjunctive techn ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Programming Metabolically Fit TILs for Immunotherapy
SBC: LIPO-IMMUNO TECH LLC Topic: NCIABSTRACT Advances in molecular biology and genetic engineering have led to the design and use of modified T cells recognize tumors to achieve significant tumor control upon adoptive cell transfer (ACT) to patients. These T cells are either transduced with tumor antigen reactive T cell receptors (TCR), or chimeric antigen receptors (CARs). Recently, a surge in studies with neo-antigen reactive T ce ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
I-RED Southeast XLerator Network
SBC: XLERATEHEALTH, LLC Topic: 500Project Summary I-RED Southeast XLerator Network, powered by XLerateHealth, LLC in collaboration with the University of Kentucky as the lead academic partner institution, proposes to develop a suite of experience-based entrepreneurship education products and commercialization education tools to address the needs of academic institutions and their faculty, researchers, innovators, and graduate/unde ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Portable Affordable Innovative and Smart Device-Coupled Electronic Fetal Monitoring System to Improve Rural Access to Obstetrics Services and Improve Outcomes in Rural Communities
SBC: Fetal Life, LLC Topic: 102PROJECT SUMMARY To ensure fetal well-being, obstetricians monitor fetal heartrate (FHR) and uterine contractions on a weekly to bi-weekly basis towards the end of pregnancy and during labor. Such monitoring is performed with an electronic fetal monitor (EFM) to decrease the development of complications while minimizing the need for unnecessary obstetric interventions. This is especially important ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Affordable sialoglycans and associated reagents for expanded chemoenzymatic production
SBC: Integrated Micro-Chromatography Systems, Inc. Topic: 300Project Summary Sialoglycans are sialic acid-containing oligosaccharides that play important biological roles in human biology and pathology and are indispensable molecular probes for research related to bacterial and viral infection, cancer metastasis, immune regulation, etc. The multifaceted functions of sialoglycans in human milk are also being explored. Nevertheless, sialoglycan-related resear ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Development of peptide nucleic acid antibiotics
SBC: NUBAD LLC Topic: NIAIDThe world is rapidly heading towards a pre-1940’s scenario when it comes to fighting infectious disease. Antimicrobial resistance is a growing problem on a global scale, greatly hampering our abilities to quell worldwide epidemics such as influenza, SARS, COVID-19, tuberculosis and malaria, as well as the simple staphylococcus infection. Unless innovative strategies are developed to produce robu ...
STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health -
Aminoglycosides with reduced ototoxicity
SBC: NUBAD LLC Topic: NIAIDPROJECT SUMMARYAminoglycosides are one of the cheapest and well-known antibiotics in clinical use for over 70 years, but one of the major limitations in their use is their ototoxicity. We are developing fast and low-cost methods to develop aminoglycosides with anti-ribosomal activities and reduced toxicity. In this project, we will identify novel aminoglycoside antibacterials, that show reduced ot ...
STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health -
mHealth for Patient Self-Management of Opioid Use Disorder
SBC: Biomedical Development Corporation Topic: NIDAPROJECT SUMMARY / ABSTRACTThe opioid crisis is an epidemic with devastating health, social, and economic consequences for the United States. From 1999–2018, almost 450,000 people died from an overdose involving any opioid, including prescription and illicit opioids. Three million US citizens and 16 million individuals worldwide have had or currently suffer from opioid use disorder (OUD). The tot ...
STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health -
Mitigating Injurious Falls in Older Adults Through Non-Injurious Fall and Gait Analysis From Floor Vibrations
SBC: ADVANCED SMART SYSTEMS AND EVALUATION TECHNOLOGIES, LLC Topic: NIAProject Summary and Abstract Falls are the leading cause of death due to injury. Falls are so common that 30% of community dwelling older adults, and 50% of residents in Care Facilities will experience a fall in the coming year. The risk of falling substantially increases for those having Alzheimer’s disease and related dementias. The financial burden is significant with fall-related costs being ...
STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health -
Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy
SBC: STRYKAGEN CORPORATION Topic: ODAbstract Duchenne Muscular Dystrophy (DMD) is a fatal muscle disease with a predicted incidence of 1 in 5000 males. DMD results from mutations in the gene encoding dystrophin, a 427 kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and laminin in the extracellular matrix. The 7β1 integrin is a transmembrane linkage system in skeleta ...
STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health